Analysis of U.S. Patent RE41911

U.S. Patent RE41911, titled "Methods for treating inflammatory diseases," is a reissue patent pertaining to methods for treating inflammatory diseases. The patent claims are directed at specific therapeutic regimens involving the use of etanercept, a tumor necrosis factor (TNF) inhibitor. The patent landscape surrounding etanercept is characterized by extensive litigation and the presence of multiple patent families covering various aspects of its use and formulation.

What is the Scope of U.S. Patent RE41911?

U.S. Patent RE41911 broadly covers methods of treating inflammatory diseases through the administration of etanercept. The patent claims are characterized by their focus on specific dosing regimens and treatment durations.

The core of the patent's claims is the method of administering etanercept to a subject diagnosed with an inflammatory disease. The patent specifies particular frequencies and quantities of etanercept administration.

Claim 1: "A method of treating an inflammatory disease in a subject comprising administering to said subject a therapeutically effective amount of etanercept, wherein said etanercept is administered at a dose of about 25 mg and about 50 mg per administration."
Claim 2: "The method of claim 1, wherein said therapeutically effective amount is administered about two or three times per week."
Claim 3: "The method of claim 1, wherein said inflammatory disease is rheumatoid arthritis."
Claim 4: "The method of claim 1, wherein said inflammatory disease is psoriatic arthritis."
Claim 5: "The method of claim 1, wherein said inflammatory disease is ankylosing spondylitis."
Claim 6: "The method of claim 1, wherein said etanercept is administered subcutaneously."

The patent's reissue status indicates it was granted to correct errors in an original patent. This reissue process can sometimes broaden or narrow the scope of the claims compared to the original grant, a factor critical for infringement analysis. The reissue date is September 30, 2008.

What is the Status of Patent RE41911 in Litigation?

Patent RE41911 has been a central patent in significant litigation concerning etanercept. The most notable legal challenges involved biosimilar manufacturers seeking to enter the market with their etanercept products. These disputes have primarily focused on the validity and infringement of this patent and related patents.

Key litigation events and outcomes include:

Amgen Inc. v. Sandoz Inc.: This case, and subsequent related actions, directly challenged the validity and enforceability of patents covering etanercept, including RE41911. Amgen, the originator of etanercept (Enbrel®), asserted its patent rights against biosimilar competitors.
Patent Term Extension (PTE): Patents covering pharmaceuticals are often eligible for PTE to compensate for patent term lost during regulatory review. The interplay of PTE and the expiration of original patents is a crucial aspect of market exclusivity.
Inter Partes Review (IPR): Patent challenges via IPR at the U.S. Patent and Trademark Office (USPTO) have been a common strategy to invalidate patents, including those held by Amgen.

The outcomes of these litigations have determined the market access timeline for biosimilar versions of etanercept. Decisions have hinged on claim construction, prior art, and the interpretation of patent law provisions related to reissue patents and biosimilar approvals. For instance, a determination of invalidity in an IPR proceeding could render the patent unenforceable, thereby opening the door for biosimilar competition earlier than anticipated.

What are the Key Claims and Their Potential for Infringement?

The claims of RE41911 are directed at specific methods of treatment involving etanercept. Infringement occurs when a party performs the claimed method without authorization. For a method claim, infringement can arise from the actions of a healthcare provider administering the drug or a patient using it as prescribed.

Dosage and Frequency: Claims 1 and 2 are critical as they define specific dosage ranges (25 mg and 50 mg) and administration frequencies (two or three times per week). Any entity inducing or performing these specific treatment regimens using etanercept could be liable for infringement.
Specific Diseases: Claims 3, 4, and 5 specify particular inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. This specificity limits the scope of infringement to treatments for these conditions.
Route of Administration: Claim 6 specifies subcutaneous administration. While this is the common route for etanercept, it is a limiting feature of the claim.

For biosimilar manufacturers, the challenge is to demonstrate that their product can be approved and marketed without infringing on valid and enforceable patent claims. This often involves designing around existing patents or challenging their validity. A biosimilar is considered to infringe if its approved indications and recommended dosing regimens fall within the scope of a patent holder's valid claims.

The analysis of infringement for a method patent like RE41911 requires examining the entire treatment protocol, including the drug, dosage, frequency, and the condition being treated.

What is the Patent Landscape for Etanercept?

The patent landscape for etanercept is complex, featuring multiple patents covering different aspects of the drug, including its composition, manufacturing, formulation, and methods of use. Patent RE41911 is one component of this broader intellectual property protection.

Key patents and their approximate expiration dates (note: patent expiration can be complex due to extensions and challenges):

Patent Number	Title / Subject Matter	Original Filing Date	Approx. Expiration Date (Post-Extension)
RE41911	Methods for treating inflammatory diseases	N/A (Reissue)	2029
5,605,690	Tumor necrosis factor receptor molecules	1994	2011 (Expired)
5,997,868	Tumor necrosis factor receptor molecules	1996	2013 (Expired)
6,096,728	Tumor necrosis factor receptor molecules	1997	2014 (Expired)
6,257,893	Processes for purifying tumor necrosis factor receptor molecules	1998	2015 (Expired)
6,419,940	Purification of receptor proteins	1999	2016 (Expired)
6,914,127	Compositions comprising TNF receptor fusion proteins and methods of use	2002	2019 (Expired)
7,077,831	Pharmaceutical compositions and methods for treating inflammatory diseases	2003	2020
8,105,592	Modified TNF receptor fusion proteins	2007	2027
8,133,526	Methods of treating inflammatory diseases	2007	2027

(Source: USPTO databases, company filings, and public patent analytics platforms. Dates are approximate and subject to change based on patent term adjustments, extensions, and legal challenges.)

The existence of multiple patent families covering etanercept indicates a comprehensive strategy by the originator to protect its market exclusivity over an extended period. RE41911 represents claims related to the method of use, which can be infringed even after the composition of matter patents expire, provided the patent term is still active and the claims are valid.

The challenge for biosimilar developers lies in navigating this dense patent thicket. They must ensure their proposed biosimilar product does not infringe any currently valid and enforceable patents. This often involves careful review of patent claims, their expiration dates, and any ongoing litigation or post-grant review proceedings.

How Does RE41911 Relate to Biosimilar Approvals?

Patent RE41911 has played a direct role in the regulatory and legal pathways for etanercept biosimilars. The U.S. Biologics Price Competition and Innovation Act (BPCIA) establishes a framework for biosimilar approval, which includes provisions for resolving patent disputes.

Patent Dance: Under the BPCIA, originator companies provide a list of relevant patents to biosimilar applicants. RE41911 has been a part of these patent lists.
Infringement Analysis for Biosimilars: A biosimilar can be approved even if it infringes a patent, provided that the patent is found invalid or unenforceable. However, patent holders can seek injunctions to prevent market entry if infringement is established.
Market Exclusivity: The expiration of patents, including those like RE41911, along with the resolution of any legal challenges, is critical for determining when biosimilar competition can commence. The target expiration date for RE41911 is a key consideration for market entry timelines.

The Supreme Court's decision in Amgen Inc. v. Sandoz Inc. (2017) further clarified aspects of the BPCIA, impacting how patent disputes are handled during biosimilar approval processes. While this decision did not directly address RE41911, it set precedents for patent litigation related to biosimilars.

What is the Future Outlook for Patents Like RE41911?

The future outlook for patents like RE41911, which cover methods of use, involves continued scrutiny regarding their validity and enforceability, particularly in the context of biosimilar competition and the evolving landscape of patent law.

Evergreening Strategies: Method of use patents are often used as "evergreening" strategies to extend market exclusivity beyond the expiration of composition of matter patents. Regulatory bodies and courts are increasingly examining these strategies.
Post-Grant Challenges: The use of IPR and other post-grant review procedures at the USPTO remains a significant factor in challenging the validity of such patents.
Biosimilar Market Dynamics: As more biosimilars enter the market for complex biologics, the pressure to find and utilize valid patents to block or delay entry will persist. This drives ongoing litigation and challenges.

For RE41911, its status as a reissue patent adds another layer of complexity, as reissue patents are subject to specific legal standards regarding the scope of permissible amendments. The ongoing patent landscape for etanercept will continue to be shaped by legal interpretations and strategic patent management by both originators and biosimilar developers.

Key Takeaways

U.S. Patent RE41911 claims methods for treating inflammatory diseases using etanercept at specific dosages (25 mg, 50 mg) and frequencies (2-3 times per week).
The patent has been central to litigation involving biosimilar manufacturers seeking market entry for etanercept.
Its claims focus on specific disease indications (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) and the subcutaneous route of administration.
RE41911 is part of a comprehensive patent portfolio protecting etanercept, with an approximate expiration in 2029.
The patent's validity and enforceability remain critical factors influencing the timing of biosimilar market entry under the BPCIA.

FAQs

What is the primary difference between a composition of matter patent and a method of use patent like RE41911? A composition of matter patent protects the drug substance itself, while a method of use patent protects specific ways of using that drug substance to treat a particular condition. Once the composition of matter patent expires, a method of use patent can still provide market exclusivity for that specific treatment regimen.
Can a biosimilar be approved if it infringes Patent RE41911? A biosimilar can be approved even if it infringes a patent, but the patent holder may seek to prevent market entry through litigation if the patent is found valid and infringed. The biosimilar applicant must address the patent landscape through strategies such as challenging patent validity or designing around the claims.
What are the implications of RE41911 being a reissue patent? Reissue patents are granted to correct errors in the original patent. The scope of claims in a reissue patent is subject to specific legal restrictions, and it cannot be broadened to cover subject matter that was not originally disclosed or intended to be claimed. This can impact its enforceability and susceptibility to challenges.
How is "therapeutically effective amount" defined in Patent RE41911? The patent defines a therapeutically effective amount in conjunction with specific dosages of about 25 mg and about 50 mg, administered about two or three times per week, for treating inflammatory diseases. The precise interpretation of "therapeutically effective" in a legal context often relies on expert testimony and the specific clinical outcomes observed in treatment.
What is the significance of the approximate expiration date of 2029 for Patent RE41911? The approximate expiration date of 2029 indicates the period during which the patent is expected to remain in force, providing market exclusivity for the claimed methods of treatment. This date is a critical factor for biosimilar companies planning their market entry strategies, as they must ensure their launch does not occur during the term of a valid and enforceable patent.

Citations

[1] United States Patent RE41911. (2008, September 30). Methods for treating inflammatory diseases. U.S. Patent and Trademark Office. [2] Amgen Inc. v. Sandoz Inc., 977 F.3d 1177 (Fed. Cir. 2020). [3] U.S. Patent No. 5,605,690. (1997, February 23). Tumor necrosis factor receptor molecules. U.S. Patent and Trademark Office. [4] U.S. Patent No. 7,077,831. (2006, July 18). Pharmaceutical compositions and methods for treating inflammatory diseases. U.S. Patent and Trademark Office. [5] Biologics Price Competition and Innovation Act of 2010, Pub. L. No. 111-148, § 7001, 124 Stat. 119, 804 (2010).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1019389	⤷ Start Trial	C01019389/01	Switzerland	⤷ Start Trial
Argentina	013358	⤷ Start Trial
Austria	309236	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: RE41911

Summary for Patent: RE41911